Nobel Prize in Medicine 2026 rewards an algae protein that lets light fire neurons

A protein that helps a single-celled pond alga swim toward light is the reason scientists can now switch one type of brain cell on or off with a flash of blue light. The Nobel Assembly at Karolinska Institutet has awarded its Physiology or Medicine prize to the three researchers who found that protein and turned it into a tool: Karl Deisseroth of Stanford University and the Howard Hughes Medical Institute, Peter Hegemann of Humboldt University of Berlin, and Georg Nagel of the University of Würzburg.

The method is called optogenetics, and it changed what brain research can prove. Neuroscientists could already see which regions became active during fear or hunger, but they could rarely show that a particular kind of neuron caused the feeling. With optogenetics they can switch those cells on in a living animal and watch the behavior appear, or switch them off and watch it stop. Labs have since used it to locate circuits for memory, pain, thirst, sleep and social behavior, and it is now being tested as a treatment for one form of blindness.

The committee cited the three “for their discoveries concerning light-gated ion channels and optogenetics.” They will share 12 million Swedish kronor equally. “Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” said Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine.

An alga that reacts 20 times faster than your eye

The story starts with Chlamydomonas, a green alga made of a single cell. Stir it into a dish, light one side, and the faint green tint drifts toward the lamp. The alga senses light through an eyespot, a tiny orange dot that contains retinal, the same light-catching molecule found in our own eyes.

Hegemann, then at the Max Planck Institute for Biochemistry in Martinsried, measured the eyespot with fine electrodes and found an electrical impulse half a millisecond after light arrived. In the human eye, light sets off a chain of chemical steps before an ion channel opens, and the whole process takes at least 10 milliseconds. The alga was more than twenty times faster.

Hegemann’s explanation was simple: one protein had to do both jobs, catching light and opening a pore for charged particles. Colleagues doubted it, because no known ion channel responded to light on its own. When his team tried to pull the protein out of the eyespot, it fell apart, and the idea stalled for years.

How they did it

The break came when Japanese researchers released genetic sequences from Chlamydomonas. Hegemann’s group found two genes that resembled known light-capturing proteins and sent them to Nagel at the Max Planck Institute for Biophysics in Frankfurt.

Nagel injected each gene into frog eggs, a standard trick that turns an egg into a factory for a foreign protein. The proteins settled on the surface of the eggs, and when Nagel shone light on them, they opened. Positively charged ions flowed through, producing an electrical current. Hegemann’s hypothesis was right. The team named the two proteins channelrhodopsin-1 and channelrhodopsin-2, and the second one opened within 0.2 milliseconds of a light pulse.

In human embryonic kidney cells and hamster cells, channelrhodopsin-2 also produced electrical signals under light. The protein behaved like a portable switch: any cell carrying the gene would answer to light.

Deisseroth was looking for exactly that. Trained as a psychiatrist, he had been struck during his clinical work by how little existing treatments helped patients with depression or schizophrenia, and he wanted to study circuits in a living brain rather than in thin slices of tissue. He wrote to Nagel asking for the channelrhodopsin-2 gene, inserted it into rat neurons growing in a dish and exposed them to blue light. The neurons fired on command, and the signal passed to neighboring cells.

His group then delivered the gene to one cell type in the motor cortex of living mice and threaded a thin optical fiber through a small hole in the skull. Pulses of light made the animals move their whiskers. In another experiment, light aimed at a suspected wakefulness circuit woke sleeping mice.

Why light beat electrodes and drugs

An electrode stimulates every neuron near its tip, whatever its type. A drug spreads through tissue and acts over minutes. Optogenetics is precise in two ways at once. The gene goes only into a chosen cell type, and light switches those cells within milliseconds, matching the speed of real nerve signals. Francis Crick, who shared a Nobel Prize for the double helix of DNA, had suggested that light would be the ideal way to control single neurons, while admitting the idea sounded far-fetched.

Precision matters because of scale. An adult human brain holds around 90 billion nerve cells, each linked to thousands of others, and neurons with unrelated jobs sit tangled together. Working with Nobel laureate Susumu Tonegawa, Deisseroth’s team reactivated the specific cells that stored a fear memory in mice, and the animals showed fear in a place where nothing threatened them. Other groups have mapped circuits for thirst, attention and fever, found that gathering pups into a nest and grooming them run on separate circuits in mice, and shown that a heart forced to beat harder can intensify anxiety.

What the prize does not settle

Optogenetics is still mainly a research tool, not a therapy. Using it in people means inserting a foreign gene into human cells, usually with a modified virus, and getting light deep into tissue, which in the brain requires an implant. Neither step is routine in patients, and the long-term safety of carrying an algal protein in human neurons has not been established.

The clearest human result is narrow. A man blind for 40 years from retinitis pigmentosa received a channelrhodopsin gene in one eye and goggles that project light pulses onto the retina. He regained enough sight to locate and count objects on a table, according to a case report in Nature Medicine in 2021. One patient is a proof of principle, not evidence that the treatment works broadly, and the trials are still running.

The prize also draws a line through a crowded field. Nobel rules allow at most three laureates per prize. The 2005 paper that first switched neurons with channelrhodopsin-2 was written in Deisseroth’s lab with Edward Boyden as first author and Feng Zhang and biophysicist Ernst Bamberg as co-authors. Gero Miesenböck at Oxford had earlier made neurons fire in response to light using a different light-sensitive system. Bamberg, Boyden and Miesenböck shared the 2013 Brain Prize for optogenetics with this year’s three laureates, but they are not part of the Nobel.

From a frog egg to Stockholm

The path to the prize ran through a handful of papers. Nagel, Hegemann and colleagues described channelrhodopsin-1 in Science in 2002 and channelrhodopsin-2 in PNAS in 2003. Deisseroth’s group reported light-controlled neurons in Nature Neuroscience in 2005, the method got its name in 2006, and the first control of neurons inside a living mouse brain followed in 2007. The fear-memory experiment with Tonegawa came in 2012.

Common questions about the 2026 Nobel Prize in Medicine

Who won the 2026 Nobel Prize in Physiology or Medicine?

Karl Deisseroth of Stanford University and the Howard Hughes Medical Institute, Peter Hegemann of Humboldt University of Berlin, and Georg Nagel of the University of Würzburg. They were honored for discoveries concerning light-gated ion channels and optogenetics, and they share 12 million Swedish kronor equally.

What is optogenetics in simple terms?

It is a way to control chosen nerve cells with light. Researchers add a gene for a light-sensitive protein, such as channelrhodopsin, to one type of neuron. Shining light of the right color then switches those cells on or off within milliseconds, which lets scientists test what each cell type does.

Is optogenetics used to treat patients?

Not as an approved therapy yet. Clinical trials are testing it to restore partial sight in people blinded by retinitis pigmentosa, and one treated patient regained the ability to locate and count objects with special goggles. Researchers also hope it could make cochlear implants more precise than electrical stimulation.

The three laureates will receive their medals and diplomas at the Nobel Prize award ceremony in Stockholm on 10 December. The alga that started it is still swimming toward light in pond water, and the protein in its eyespot now opens on command in laboratories around the world.

Reference: Nagel et al., “Channelrhodopsin-2, a directly light-gated cation-selective membrane channel,” PNAS, 2003. DOI: 10.1073/pnas.1936192100. Boyden et al., “Millisecond-timescale, genetically targeted optical control of neural activity,” Nature Neuroscience, 2005. DOI: 10.1038/nn1525

Tags: neuroscience, Nobel Prize, channelrhodopsin, Georg Nagel, Karl Deisseroth, optogenetics